TEACHER
- Organizing Committee Members
- International Committee
- Company Presentations
- Entrepreneur Pitch
- Session 1&2 – Global Biotech Development
- Session 3 – International Collaboration Strategy
- Session 4 – Exit Strategies for Early Stage New Drug Companies
- Session 5 – New Modalities to Cure
- Session 6 - BIO Asia–Taiwan 2022 Opening & Award Ceremony
- Session 7 - Future Pandemic Preparedness
- Session 8 – Healthcare Innovation Strategy
- Session 9 – Winning the Global Competition with Taiwanese DNA
- Session 10 – AI & Digital Health
- Session 11 – Novel Platforms for Biopharma Discovery
- Session 12 – Biologics Product Development and Manufacturing
- Session 13 – Advances in Cell & Gene Therapy
- Session 14 – CDMO Business for Small Molecules
- Special Forum – Emerging Opportunities when ICT meets BIO
- Session 16- AFOB Net Zero Emission Bioeconomy
- Session 17-Life Science Ventures in Australia
- Session 18-Life Science Ventures in India
- Session 19-Life Science Ventures in Japan
- Session 20-Life Science Ventures in Singapore
- Session 21-Life Science Ventures in UK
- Session 22–Life Science Ventures in Lithuania
- Satellite Conference
Edward Deng
Session 9 – Winning the Global Competition with Taiwanese DNA
Date：28 July (Thursday)
Time: 14:00 – 15:30 (GMT+8)
Edward Deng
CEO
H2 Inc.
Ed Deng is the CEO of Health2Sync, which he co-founded after witnessing many in his family battle diabetes and learning what works in managing the disease. Prior to Healt2Sync, Ed was Chief Marketing Officer of Hesine Technologies, an end-to-end push platform for mobile devices, which was acquired by Link Motion. Ed started his career as an Investment Banker at Lehman Brothers’s Technology Mergers & Acquisitions Group in Palo Alto, CA. Ed obtained a BS in Commerce-Finance from McIntire School of Commerce at The University of Virginia. Ed currently serves on the Global Advisory Board of McIntire School of Commerce.
Speech title & Synopsis
Panel Discussion: How Do We Survive and Thrive?
.
